ABA Chemicals Corporation (SHE:300261)
China · Delayed Price · Currency is CNY 5.99
+0.02 (0.34%)
May 8, 2026, 10:05 AM CST
ABA Chemicals Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,307 | 1,168 | 1,224 | 1,887 | 1,987 |
Other Revenue | - | 33.89 | 54.83 | 114.15 | 84.81 |
| 1,307 | 1,202 | 1,279 | 2,001 | 2,072 | |
Revenue Growth (YoY) | 8.73% | -6.00% | -36.09% | -3.42% | 3.42% |
Cost of Revenue | 1,067 | 1,066 | 1,000 | 1,401 | 1,500 |
Gross Profit | 240.6 | 135.78 | 278.48 | 599.68 | 571.9 |
Selling, General & Admin | 171.62 | 184.82 | 193.6 | 192.45 | 201.45 |
Research & Development | 116.74 | 120.02 | 117.65 | 130.37 | 123.23 |
Other Operating Expenses | 1.97 | 4.15 | 11.68 | 13.37 | 12.58 |
Operating Expenses | 290.33 | 315.05 | 346.38 | 349.26 | 338.95 |
Operating Income | -49.73 | -179.27 | -67.9 | 250.42 | 232.94 |
Interest Expense | - | -34.42 | -34.57 | -38.1 | -41.3 |
Interest & Investment Income | - | 10.24 | 15.82 | 3.7 | 3.83 |
Currency Exchange Gain (Loss) | - | 4.54 | 12.96 | 51.51 | -13.78 |
Other Non Operating Income (Expenses) | -70.98 | -4.48 | 0.08 | -1.01 | -0.9 |
EBT Excluding Unusual Items | -120.7 | -203.41 | -73.61 | 266.52 | 180.8 |
Impairment of Goodwill | - | -106.04 | -42.52 | - | - |
Gain (Loss) on Sale of Investments | -25.19 | -4.25 | 28.52 | -25.14 | 34.66 |
Gain (Loss) on Sale of Assets | 0.16 | 0.3 | 3.83 | 0.93 | -0.17 |
Asset Writedown | -52.41 | -0.36 | -0.08 | -0.21 | -1.89 |
Other Unusual Items | - | 4.84 | -4.95 | 2.41 | 5.25 |
Pretax Income | -198.14 | -308.91 | -88.82 | 244.51 | 218.65 |
Income Tax Expense | -13.56 | -44.78 | -16.46 | 24.97 | 23.13 |
Earnings From Continuing Operations | -184.58 | -264.13 | -72.36 | 219.53 | 195.51 |
Minority Interest in Earnings | 25.07 | 6.43 | -9.93 | -16.59 | -13.66 |
Net Income | -159.51 | -257.7 | -82.29 | 202.95 | 181.85 |
Net Income to Common | -159.51 | -257.7 | -82.29 | 202.95 | 181.85 |
Net Income Growth | - | - | - | 11.60% | 12.94% |
Shares Outstanding (Basic) | 956 | 955 | 955 | 955 | 955 |
Shares Outstanding (Diluted) | 956 | 955 | 955 | 955 | 955 |
Shares Change (YoY) | 0.09% | 0.01% | 0.01% | 0.00% | -0.28% |
EPS (Basic) | -0.17 | -0.27 | -0.09 | 0.21 | 0.19 |
EPS (Diluted) | -0.17 | -0.27 | -0.09 | 0.21 | 0.19 |
EPS Growth | - | - | - | 11.60% | 13.26% |
Free Cash Flow | -128.4 | 57.54 | -258.13 | -108.89 | 331.48 |
Free Cash Flow Per Share | -0.13 | 0.06 | -0.27 | -0.11 | 0.35 |
Dividend Per Share | - | 0.050 | - | 0.050 | - |
Gross Margin | 18.41% | 11.29% | 21.77% | 29.97% | 27.61% |
Operating Margin | -3.80% | -14.91% | -5.31% | 12.52% | 11.24% |
Profit Margin | -12.20% | -21.44% | -6.44% | 10.14% | 8.78% |
Free Cash Flow Margin | -9.82% | 4.79% | -20.18% | -5.44% | 16.00% |
EBITDA | 89.48 | -45.84 | 65.64 | 382.02 | 359.14 |
EBITDA Margin | 6.84% | -3.81% | 5.13% | 19.09% | 17.34% |
D&A For EBITDA | 139.21 | 133.43 | 133.54 | 131.6 | 126.2 |
EBIT | -49.73 | -179.27 | -67.9 | 250.42 | 232.94 |
EBIT Margin | -3.80% | -14.91% | -5.31% | 12.52% | 11.24% |
Effective Tax Rate | - | - | - | 10.21% | 10.58% |
Revenue as Reported | - | 1,202 | 1,279 | 2,001 | 2,072 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.